David Liebowitz Email

SVP, Clinical Development and Medical Affairs . Xencor

Current Roles

Employees:
356
Revenue:
$77.3M
About
Antibodies by Design Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics antibodies that target new biological mechanisms and are more potent, safer and longer lasting to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs.
Xencor Address
465 North Halstead Street
Monrovia, CA
United States
Xencor Email

Past Companies

XencorSenior Vice President, Clinical Development and Medical Affairs
XencorVice President Clinical Development and Medical Affairs
Liebowitz Consulting LLCOwner / Principal

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.